Axsome Therapeutics, Inc. (AXSM) Profit Margins
Over the twelve months to 2026-06-30, Axsome Therapeutics, Inc. (AXSM) had gross margin 93.2%, operating margin -24.0%, net margin -24.7%, free cash flow margin -9.3%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AXSMAxsome Therapeutics, Inc.Follow AXSM — free
—
Price chart with a free account
- Market cap
- 7.6B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 8 days
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Gross margin | 89.6% | 90.4% | 91.4% | 92.6% | 93.2% | |
| Operating margin | -359.3% | -85.7% | -72.7% | -26.1% | -24.0% | |
| Net margin | -374.0% | -88.4% | -74.5% | -28.7% | -24.7% | |
| FCF margin | -234.3% | -53.8% | -33.4% | -14.7% | -9.3% |
USD millions · SEC XBRL
Axsome Therapeutics, Inc. — questions
- What is Axsome Therapeutics, Inc.'s gross margin?
- 93.2% over the twelve months to 2026-06-30.
- What is Axsome Therapeutics, Inc.'s operating margin?
- -24.0% over the twelve months to 2026-06-30.
- What is Axsome Therapeutics, Inc.'s net profit margin?
- -24.7% over the twelve months to 2026-06-30.
Every figure on this page comes from Axsome Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.